CONCLUSION
Our study is the first study investigating periostin levels in patients with COVID-19, and it was found to be significantly higher in patients with COVID-19. Periostin can be used as a new biomarker; however, we believe that further studies with larger numbers of cases and longer follow-up periods are needed for its use in the follow-up and severity prediction of the disease.